Datum: 23.2.2009
When a promising cancer drug reached clinical trials in the 1990s, researchers were disappointed by the debilitating side effects that limited the trials. The drug inhibited a family of enzymes known as matrix metalloproteinases (MMPs). Now, researchers at Rensselaer Polytechnic Institute have shown that creating drugs that inactivate a different part of the MMP enzyme could have the capacity to target the tumor without the damaging side effects. Their findings, which hold promise for improved cancer therapies, were published Feb. 5 in the online Early Edition of the Proceedings of the National Academy of Sciences (PNAS).
More news.rpi.edu
BIOFORUM 2010
Lodz, Poland, May 19-21, 2010
Mendel lectures: How DNA recombination maintains genome integrity
Mendel museum, Brno, April 15, 2010
Mendel lectures: Germ cell specification in mice
Mendel museum, Brno, April 29, 2010
The Second International Conference on Biological and Environmental Sciences (2ICBES)
Mansoura and Luxor, Egypt, March 15-20, 2010
XGen Congress
San Diego, CA, United States, March 15-19, 2010
Drug Discovery Technology World Asia 2010
Singapore, March 16-19, 2010
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
© 2006 South Moravian Innovation Centre
Interesting biotechnology content:
BIO.com - Biotechnology News, Jobs, Software, Protocols, Events
ScienceWeek - Biotechnology Science since 1997
Gene Variation That Lets People Get by on Fewer Zees Is Transferred into Mice
Unusual metals could forge new cancer drugs